Searched for
DR REDDYS LAB
Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...- Alkem rolls out single-shot semaglutide syringes at Rs 350 for diabetes, weight lossAlkem Laboratories has launched semaglutide in single-shot pre-filled syringes in India. This makes treatment more accessible and affordabl...
- Strong revenue growth fails to shield India Inc margins in March quarterCorporate India's March 2026 quarter results showed a mixed performance. While revenues grew strongly, input cost inflation and a weaker ru...
- Rising bond yields, oil prices keeping markets on edge; selective bets still emerging: Pankaj PandeyGlobal markets are under pressure due to rising bond yields and geopolitical tensions. Higher crude oil prices are a key concern, potential...
- Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...
- Reddy Pharma loses 'name' in Delhi HC rulingThe Delhi High Court has ruled against Reddy Pharmaceuticals. The court upheld a decision to remove 'Reddy' from the company's name. Reddy ...
- ET Women Conclave 2026 spotlights leadership, reinvention, and powerful conversationsThe ET Women Conclave 2026 celebrated inspiring leaders, entrepreneurs, and changemakers with dialogues on authenticity, wellness, and impa...
- Dr Reddy's Laboratories Q4 Results: Cons PAT falls 86% YoY to Rs 221 crore, revenue dips 12%; Rs 8 per share dividend announcedDr Reddy's Laboratories Q4 Results: Dr. Reddy's Laboratories reported a consolidated net profit at Rs 221 crore in the March-ended quarter ...
- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- Sun Pharma to acquire Organon for $11.75 billion in India’s biggest pharma dealSun Pharma, led by Dilip Shanghvi, has agreed to acquire US-based Organon in an all-cash deal worth $11.75 billion, marking the largest acq...
- Dr Reddy's gets nod to roll out generic oral semaglutide drug"The formulation was clinically evaluated in a head-to-head comparative study conducted in India, which established the non-inferiority to ...
- Dr Reddy's Laboratories Q2 Results: Profit rises 7% YoY to Rs 1,347 crore, revenue up 10%Dr Reddy's Laboratories Q2 Results: Generic drugmaker Dr Reddy's Labs reported 7% growth in its net profit at Rs 1,347 crore in the Septemb...
- Dr. Reddy's Laboratories Q1 Results: PAT rises 2% YoY to Rs 1,418 crore, revenue jumps 11%Dr Reddy's Laboratories Q1 Results: Pharma major Dr. Reddy's Laboratories reported a marginal 2% year-on-year (YoY) growth in its consolida...
- Dr Reddy's Labs Q4 Results: Cons PAT jumps 22% to Rs 1,594 crore; Rs 8 per share dividend announcedDr Reddy's Labs Q4 Results: Dr Reddy's Laboratories on Friday reported a consolidated net profit growth of 22% to Rs 1,594 crore in Q4FY25 ...
- Dr Reddy's Labs Q3 Results: Cons PAT rises 2% YoY to Rs 1,413 crore, revenue up 16%Dr Reddy's Labs Q3 Results: Dr Reddy's Laboratories on Thursday reported a 2% year-on-year growth in its December quarter consolidated net ...
- Dr Reddy's Labs shares up 3% after Q2 results. What should investors do?Dr. Reddy's Labs reported a 15% decline in Q2 net profit, despite a 17% rise in revenue driven by global generics. While analysts acknowled...
- Dr. Reddy's Lab Q1 Results: Profit down 1% to Rs 1,392 crore but revenue jumps 14%Dr. Reddy's Lab Q1 Results: While announcing the quarterly numbers, the company's board also approved split of equity shares in the ratio o...
- Dr. Reddy's Labs announces share buy back, stock jumps 4%The company said the price represents an 18.6% premium to the average closing price of shares for the two weeks up to February 16, 2016.
- Buy Dr Reddy's Lab with target price of Rs 2350: Shardul KulkarniDr Reddy's Lab Ltd is a 'BUY' call with a target of Rs 2350 and a stop loss of Rs 2180.
- Sell Dr Reddy's Lab with target price of Rs 2160: Sandeep WagleSell Dr Reddy's Lab at a stop of Rs 2250.
Load More
